Abstract
Objective: The objective of this study was to develop a stability-indicating reverse-phase high-performance liquid chromatography (RP-HPLC) method for the estimation of ledipasvir (LDP) in bulk and tablet formulation.
 Methods: Stability-indicating RP-HPLC method was developed and validated for the estimation of LDP in bulk and tablet formulation. RP-HPLC was carried out on HiQ SiL C18 columns (250 mm × 4.6 mm, 5 μ particle size) using mobile phase acetonitrile:1 mM ammonium acetate buffer in the ratio of 90:10 v/v at a flow rate of 1 ml/min. The analytes were monitored using MD 2010 PDA detector at 333 nm.
 Results: The retention time was found to be 3.843 min. The proposed method was found to be having linearity in the concentration range of 5–30 μg/ml. The number of theoretical plates obtained was 4236.50 which indicate the efficient performance of the column. The limit of detection was 0.305 μg/ml and limit of quantification was 0.923 μg/ml, which indicate the sensitivity of the method; the high percentage recovery indicates that the proposed method is highly accurate. The developed method has been validated according to the ICH guidelines and found to be simple, specific, precise, and accurate.
 Conclusion: The proposed method is precise, accurate, and stability indicating. Therefore, the proposed method can be used for routine quality control and analysis of LDP during stability studies in bulk samples and tablet dosage forms.
Highlights
Ledipasvir (LDP) is chemically methyl N-[(2S)-1-[(6S)-6-[5[9,9-difluoro-7-[2-[(1S,2S,4R)-3-[(2S)-2-(methoxycarbonylam ino)-3-methylbutanoyl]-3-azabicyclo[2.2.1]heptan-2-yl]-3Hbenzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4] heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate
LDP in combination with sofosbuvir is used for the treatment of chronic hepatitis C, genotypes 1-6, usually in combination with other medications depending on the specific genotype [1,2]
It can be concluded that the proposed method is precise, accurate, and stability indicating
Summary
Ledipasvir (LDP) is chemically methyl N-[(2S)-1-[(6S)-6-[5[9,9-difluoro-7-[2-[(1S,2S,4R)-3-[(2S)-2-(methoxycarbonylam ino)-3-methylbutanoyl]-3-azabicyclo[2.2.1]heptan-2-yl]-3Hbenzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4] heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate. It is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. LDP in combination with sofosbuvir is used for the treatment of chronic hepatitis C, genotypes 1-6, usually in combination with other medications depending on the specific genotype [1,2]. A literature review revealed few spectrophotometric, reverse-phase high-performance liquid chromatography (RP-HPLC), stability-indicating RP-HPLC, and UPLCESI MS/MS [3-13] methods for the estimation of LDP. The purpose of this work was to develop a simple basic rapid and economic stabilityindicating RP-HPLC method for the determination of LDP in its bulk and pharmaceutical dosage form so as to provide better scope for further research on the drug (Fig. 1)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Journal of Pharmaceutical and Clinical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
